News Center

News Center

Company News

Industry Information

Home>News Center

News Center

News Center

Company News

惠和生物CC312三抗自免IND申请获批

快讯：惠和自免IND申请获CDE正式受理！

惠和生物闭门学术研讨沙龙成功举办

Industry Information

默沙东13亿美元引进同润生物CD3xCD19双抗CN201

惠和生物首个三抗药物获FDA批准进入临床，CD3/CD28共刺激信号三抗备受关注

赛诺菲Nature发表HER2/CD3/CD28三抗作用机制

Nature：免疫治疗新突破，赛诺菲开发三特异性抗体，提高T细胞抗癌效果

CDE新规加快创新药上市！恒瑞、强生、武田等90款产品谁将率先冲线？

押注NK细胞疗法，Intellia与ONK达成超9亿美元合作，开发CRISPR基因编辑癌症细胞疗法

Technology Platform

COPYRIGHT@CytoCares 2022　DIGITAL By VTHINK

Legal Statement 沪ICP备2022004270号

+86 021-50582090 info@cytocares.com Follow WeChat

CytoCares Technology Platform Pipeline Contact Us

Legal Statement 沪ICP备2022004270号

COPYRIGHT@CytoCares 2022.
DIGITAL By VTHINK